Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 61 out of 100. How common it is

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Abstract The prevalence of Alzheimer’s disease neuropathological changes (ADNCs), the leading cause of cognitive impairment, remains uncertain. Recent blood-based biomarkers enable scalable assessment of ADNCs 1 . Here we measured phosphorylated tau at threonine 217 in 11,486 plasma samples from a Norwegian population-based cohort of individuals over 57 years of age as a surrogate marker for ADNCs. The estimated prevalence of ADNCs increased with age, from less than 8% in people 58–69.9 years of age to 65.2% in those over 90 years of age. Among participants aged 70 years or older, 10% had preclinical Alzheimer’s disease, 10.4% had prodromal Alzheimer’s disease and 9.8% had Alzheimer’s disease dementia. Furthermore, among those 70 years of age or older, ADNCs were present in 60% of people with dementia, in 32.6% of those with mild cognitive impairment and in 23.5% of the cognitively unimpaired group. Our findings suggest a higher prevalence of Alzheimer’s disease dementia in older individuals and a lower prevalence of preclinical Alzheimer’s disease in younger groups than previously estimated 2 .

What this study adds

Evidence grade: Moderate

Using plasma p-tau217 as a surrogate marker, the estimated prevalence of Alzheimer's disease neuropathological changes rose with age, from less than 8% in people aged 58–69.9 to 65.2% in those over 90. Reported effect size: 65.2%; 10.4%; 9.8%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Aarsland, D., Sunde, A. L., Tovar, D., Leuzy, A., Fladby, T., Zetterberg, H., et al. (2025). Prevalence of Alzheimer’s disease pathology in the community. Nature. https://doi.org/10.1038/s41586-025-09841-y

Vancouver

Aarsland D, Sunde AL, Tovar D, Leuzy A, Fladby T, Zetterberg H, et al. Prevalence of Alzheimer’s disease pathology in the community. Nature. 2025. doi:10.1038/s41586-025-09841-y. PMID: 41407852.

BibTeX

@article{aarsland2025-41407852,
  author  = {Aarsland, Dag and Sunde, Anita Lenora and Tovar, Diego and Leuzy, Antoine and Fladby, Tormod and Zetterberg, Henrik and Blennow, Kaj and Tan, Kübra and others},
  title   = {{Prevalence of Alzheimer’s disease pathology in the community}},
  journal = {Nature},
  year    = {2025},
  doi     = {10.1038/s41586-025-09841-y},
  pmid    = {41407852},
  url     = {https://doi.org/10.1038/s41586-025-09841-y}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

Using plasma p-tau217 as a surrogate marker, the estimated prevalence of Alzheimer's disease neuropathological changes rose with age, from less than 8% in people aged 58–69.9 to 65.2% in those over 90. The findings suggest a higher prevalence of Alzheimer's disease dementia in older individuals and a lower prevalence of preclinical Alzheimer's disease in younger groups than previously estimated.

Study details

How this study scored 61/100
How this study's score is builtJournal tier 10 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 2 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 3 of 5; Impact for its field and year 5 of 6; Cited by studies here 2 of 6; Still being cited 2 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 61 of 100.61 of 100 points earned39 not earned

Published in a top-tier journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 10 / 10 Tier 1 — top-tier general journal (Nature)
Journal's citation record 4 / 4 Nature: journal h-index 1,841 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 46 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 15.3 citations a year over 3 year(s) since 2025
Impact for its field and year 5 / 6 Cited 29.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 4 other studies in this library
Still being cited 2 / 4 Cited 46 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Nicholas James Ashton: h-index 91 (OpenAlex, whole career)
Institution's track record 2 / 3 University College London: institution h-index 2,029 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 30 institution(s) in 12 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41407852)
Free to read 2 / 2 Free to read
Total 61 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.

In the news

1 news article on alzhub's news page cites this paper.

Later studies that cite this one

4 studies in the alzhub library list this one in their references.

Related studies in How common it is from nearby years

Also in How common it is

80 studies in the library are filed under How common it is with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The How common it is hub.

Similar studies

More on How common it is

See all studies in How common it is →